tirzepatide triple agonist Agonism Based Therapies for Obesity 🧬 The Future of Weight

Its not clearand clinical trials havent shown that taking a GLP-1 medication will reduce your Alzheimers risk, says Clifford Segil, DO , a neurologist at Providence Saint Johns Health Center in Santa Monica, California

Statements Author contributions YQ: Formal analysis, Investigation, Methodology, Validation, Visualization, Writing original draft, Writing review & editing

Heart rate increases slightly more with tirzepatide (average 2-3 bpm) than with semaglutide, but this change has not translated to increased cardiac events in published trials

Originally developed for treating diabetes, tirzepatide has shown significant effectiveness as an obesity treatment, helping patients achieve meaningful weight reduction while improving overall metabolic function